Gabelli Starts bluebird bio (BLUE) at Buy (Earlier)
Get Alerts BLUE Hot Sheet
Price: $1.37 --0%
Rating Summary:
13 Buy, 16 Hold, 3 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 7 | Down: 3 | New: 1
Rating Summary:
13 Buy, 16 Hold, 3 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 7 | Down: 3 | New: 1
Join SI Premium – FREE
Gabelli initiates coverage on bluebird bio (NASDAQ: BLUE) with a Buy rating and a price target of $239.00.
Analyst Jing He is positive on bb2121. They estimate the BCMA CAR-T market to be $3.9bn in MM in 2023 and bb2121/bb21217 will obtain 45% market share. They expect the therapy to reach peak sales of $3.0bn in 2027. bluebird is entitled to 50% of US commercial rights and ~10% ex-US royalties.
For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.
Shares of bluebird bio closed at $178.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Xeris Pharmaceuticals (XERS) at Outperform, 'successful commercial execution will continue to drive top-line growth'
- BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
- Goldman Sachs Upgrades BDO Unibank, Inc (BDO:PM) (BDOUY) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!